Vertex Pharmaceuticals Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessNext earnings: Thu, Feb 11, 2027, after the market closes · estimates and history
Vertex Pharmaceuticals Inc Forecast
Vertex Pharmaceuticals Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 38.0% a year, a typical one-standard-deviation range is 9,588–10,672 over a week, 9,020–11,240 over a month and 6,285–13,975 over a year. (Signals as of 5 Nov 2026.)
Vertex Pharmaceuticals Inc Price Chart
Vertex Pharmaceuticals Inc Factors
Research on Vertex Pharmaceuticals Inc
Explore MacroFinance macro & markets research and analysis.
Vertex Pharmaceuticals Inc Trading Strategies
28 backtested tactical asset allocation strategies hold EEM (emerging markets), the closest tradable exposure to Vertex Pharmaceuticals Inc; 2 of them are invested now. Strategies currently invested are listed first.
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow Vertex Pharmaceuticals Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Vertex Pharmaceuticals Inc (Mexico)
Vertex Pharmaceuticals Inc is a listed security in Mexico. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Vertex Pharmaceuticals Inc
Frequently asked questions
What is Vertex Pharmaceuticals Inc?
What is the latest Vertex Pharmaceuticals Inc price?
Is Vertex Pharmaceuticals Inc in an uptrend?
How volatile is Vertex Pharmaceuticals Inc?
What factors affect Vertex Pharmaceuticals Inc?
Which trading strategies trade Vertex Pharmaceuticals Inc?
How are Vertex Pharmaceuticals Inc returns analysed?
Where can I download free Vertex Pharmaceuticals Inc historical data?
Free Vertex Pharmaceuticals Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Vertex Pharmaceuticals Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.VRTX.MX&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 9936 |
| 2026-11-19 | 9925 |
| 2026-11-18 | 10240 |
| 2026-11-17 | 10240 |
| 2026-11-13 | 10240 |
| 2026-11-12 | 10240 |
| 2026-11-11 | 10240 |
| 2026-11-10 | 10240 |
| 2026-11-09 | 10060.6 |
| 2026-11-06 | 10060.6 |
About this stock
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.